‌

US Patent 8343928 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus

Patent 8343928 was granted and assigned to Seagen on January, 2013 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Svetlana O. Doronina6

Toni Beth Kline6

Date of Patent

January 1, 2013

Patent Application Number

11994809

Date Filed

July 7, 2006

Patent Citations Received

US Patent 12102689 Anti-CD22 antibody-maytansine conjugates and methods of use thereof

1

US Patent 11667696 Selective reduction of proteins

2

US Patent 11767365 BCMA antibodies and use of same to treat cancer and immunological disorders

US Patent 11866496 Humanized anti-CD79B antibodies and immunoconjugates and methods of use

3

US Patent 11944689 Drug conjugates with self-stabilizing linkers having improved physiochemical properties

4

US Patent 12016842 Methods of using anti-CD79b immunoconjugates

5

Patent Primary Examiner

Cecilia J. Tsang

Patent abstract

Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8343928 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.